Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany

Eidt-Koch D, Mittendorf T, Greiner W (2009)
BMC Pediatrics 9(1): 55.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA
Autor*in
Eidt-Koch, Daniela; Mittendorf, Thomas; Greiner, WolfgangUniBi
Abstract / Bemerkung
Background: Quality of life is recognized as an important additional outcome measure in clinical trials and health economic evaluations. The EQ-5D is an important generic health outcome instrument often used for economic evaluations as a complement with disease-specific outcome measures. In this study quality of life data was assessed using the EQ-5D-Y (new EQ-5D version for children and adolescents) and the Cystic Fibrosis Questionnaire (CFQ). The objective of the study is to evaluate the cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. Methods: In 2006 a multi-centre study was conducted in four cystic fibrosis centres in Germany. Quality of life data from 96 patients between eight and seventeen years was collected using the EQ-5D-Y as a generic outcome instrument and the Cystic Fibrosis Questionnaire (CFQ) as a disease-specific instrument. Results of both instruments were compared by statistical analyses using Spearman's rank correlations. Results: 44.6% of the patients stated that they had no problems in any of the EQ-5D-Y dimensions. Several low to high correlations between separate dimensions and the visual analogue scale of the EQ-5D-Y and the different scales of the CFQ for children, their parents and adolescents can be presented in this paper. Looking at the five EQ-5D-Y dimensions the highest correlation (rS = 0.625, p = 0.01) was found between the dimension 'mobility' and the CFQ scale 'physical functioning' in adolescent patients. The overall highest correlation was found between the 'subjective health perception' and the visual analogue scale (rS = 0.744, p = 0.01) in adolescent patients older than 13 years. Conclusion: The EQ-5D-Y can be considered a cross-sectional valid generic health outcome instrument which reflects differences in health according to the progression of the life-long chronic disease cystic fibrosis.
Erscheinungsjahr
2009
Zeitschriftentitel
BMC Pediatrics
Band
9
Ausgabe
1
Seite(n)
55
ISSN
1471-2431
Page URI
https://pub.uni-bielefeld.de/record/1783809

Zitieren

Eidt-Koch D, Mittendorf T, Greiner W. Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. BMC Pediatrics. 2009;9(1):55.
Eidt-Koch, D., Mittendorf, T., & Greiner, W. (2009). Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. BMC Pediatrics, 9(1), 55. https://doi.org/10.1186/1471-2431-9-55
Eidt-Koch, Daniela, Mittendorf, Thomas, and Greiner, Wolfgang. 2009. “Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany”. BMC Pediatrics 9 (1): 55.
Eidt-Koch, D., Mittendorf, T., and Greiner, W. (2009). Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. BMC Pediatrics 9, 55.
Eidt-Koch, D., Mittendorf, T., & Greiner, W., 2009. Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. BMC Pediatrics, 9(1), p 55.
D. Eidt-Koch, T. Mittendorf, and W. Greiner, “Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany”, BMC Pediatrics, vol. 9, 2009, pp. 55.
Eidt-Koch, D., Mittendorf, T., Greiner, W.: Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. BMC Pediatrics. 9, 55 (2009).
Eidt-Koch, Daniela, Mittendorf, Thomas, and Greiner, Wolfgang. “Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany”. BMC Pediatrics 9.1 (2009): 55.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Copyright Statement:
Dieses Objekt ist durch das Urheberrecht und/oder verwandte Schutzrechte geschützt. [...]
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2019-09-06T08:48:53Z
MD5 Prüfsumme
284ba96c095718ec1a4c3fb7646721a0


22 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

EQ-5D-Y-5L: developing a revised EQ-5D-Y with increased response categories.
Kreimeier S, Åström M, Burström K, Egmar AC, Gusi N, Herdman M, Kind P, Perez-Sousa MA, Greiner W., Qual Life Res 28(7), 2019
PMID: 30739287
Health-related quality of life by allergy symptoms in elementary school students.
Kim SK, Jo MW, Kim SH., Health Qual Life Outcomes 16(1), 2018
PMID: 29764459
Population health status based on the EQ-5D-Y-3L among adolescents in Sweden: Results by sociodemographic factors and self-reported comorbidity.
Åström M, Persson C, Lindén-Boström M, Rolfson O, Burström K., Qual Life Res 27(11), 2018
PMID: 30196340
Randomised controlled trial and economic evaluation of the 'Families for Health' programme to reduce obesity in children.
Robertson W, Fleming J, Kamal A, Hamborg T, Khan KA, Griffiths F, Stewart-Brown S, Stallard N, Petrou S, Simkiss D, Harrison E, Kim SW, Thorogood M., Arch Dis Child 102(5), 2017
PMID: 28003178
Randomised controlled trial evaluating the effectiveness and cost-effectiveness of 'Families for Health', a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years.
Robertson W, Fleming J, Kamal A, Hamborg T, Khan KA, Griffiths F, Stewart-Brown S, Stallard N, Petrou S, Simkiss D, Harrison E, Kim SW, Thorogood M., Health Technol Assess 21(1), 2017
PMID: 28059054
Valuation of Child Health-Related Quality of Life in the United States.
Craig BM, Greiner W, Brown DS, Reeve BB., Health Econ 25(6), 2016
PMID: 25926161
Valuation of Child Behavioral Problems from the Perspective of US Adults.
Craig BM, Brown DS, Reeve BB., Med Decis Making 36(2), 2016
PMID: 26209476
Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis.
Solem CT, Vera-Llonch M, Liu S, Botteman M, Castiglione B., Health Qual Life Outcomes 14(), 2016
PMID: 27097977
Measuring health-related quality of life with the EQ-5D-Y instrument in children and adolescents with asthma.
Bergfors S, Åström M, Burström K, Egmar AC., Acta Paediatr 104(2), 2015
PMID: 25393977
The Value Adults Place on Child Health and Functional Status.
Craig BM, Brown DS, Reeve BB., Value Health 18(4), 2015
PMID: 26091599
Can adult weights be used to value child health states? Testing the influence of perspective in valuing EQ-5D-Y.
Kind P, Klose K, Gusi N, Olivares PR, Greiner W., Qual Life Res 24(10), 2015
PMID: 25894060
Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.
Angelis A, Kanavos P, López-Bastida J, Linertová R, Nicod E, Serrano-Aguilar P, BURQOL-RD Research Network., BMC Health Serv Res 15(), 2015
PMID: 26416027
Mapping EQ-5D utility scores from the PedsQL™ generic core scales.
Khan KA, Petrou S, Rivero-Arias O, Walters SJ, Boyle SE., Pharmacoeconomics 32(7), 2014
PMID: 24715604
Measuring health outcomes of adolescents: report from a pilot study.
Oluboyede Y, Tubeuf S, McCabe C., Eur J Health Econ 14(1), 2013
PMID: 21785871
How about your peers? Cystic fibrosis questionnaire data from healthy children and adolescents.
Tibosch MM, Sintnicolaas CJ, Peters JB, Merkus PJ, Yntema JB, Verhaak CM, Vercoulen JH., BMC Pediatr 11(), 2011
PMID: 21989260

11 References

Daten bereitgestellt von Europe PubMed Central.

Quality of life – evaluation criteria for children with chronic conditions in medical care
Bullinger M, Schmidt S, Petersen C, Ravens-Sieberer U., 2006

Stern M, Sens B, Wiedemann B, Busse O, Damm G, Wenzlaff P., 2009
Validating the EQ-5D with time trade off for the German population.
Greiner W, Claes C, Busschbach JJ, von der Schulenburg JM., Eur J Health Econ 6(2), 2005
PMID: 19787848
Translation and testing of a Spanish Child-Friendly version of EQ-5D and the appropriateness of the EQ-5D
Gusi N, Badía X, Herdman M, Olvares P., 2006
Translation and testing of an Italian Child-Friendly version of EQ-5D
Scalone L, Cavrini G, Pacelli B, Mattivi A., 2006
The Contribution of lexical analyses of the wording in cognitive interviews during the CF-EQ-5D italian translation
Tomasetto C, Matteucci MC, Selleri P, Cavrini G., 2006
Age-appropriateness of the EQ-5D adult and child-friendly version – Testing the feasibility, reliability and validity in children and adolescents
Wille N, Ravens-Sieberer U., 2006
Establishing definitions of the concepts included in CF-EQ-5D – A revision of the "Definition of EQ-5D concepts" for adults
Wille N, Ravens-Sieberer U., 2006
Proposal on a core set of instruments for validation of the international child-friendly EQ-5D
Wille N, Ravens-Sieberer U., 2006
The concurrent validity of the Child Friendly version of the EQ-5D when used with high school English speaking children in South Africa
Jelsma J, Coppez P, Jehosofat T, Lenders C., 2006
The revised German Cystic Fibrosis Questionnaire: validation of a disease-specific health-related quality of life instrument.
Wenninger K, Aussage P, Wahn U, Staab D; German Cystic Fibrosis Questionnaire study group., Qual Life Res 12(1), 2003
PMID: 12625520
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 19715563
PubMed | Europe PMC

Suchen in

Google Scholar